2023-08-14 07:05:04 ET
- BioXcel Therapeutics press release ( NASDAQ: BTAI ): Q2 GAAP EPS of -$1.83 misses by $0.11 .
- Revenue of $0.46M misses by $0.01M .
- Cash and cash equivalents totaled $127.5 million as of June 30, 2023. As noted above, the Company is undertaking a strategic reprioritization, which includes a reduction in force of more than 50%, that is expected to reduce expenses significantly. In the absence of additional capital becoming available to the Company under the strategic financing agreements or otherwise, the Company estimates that its current cash and cash equivalents will last through mid-2024.
For further details see:
BioXcel Therapeutics GAAP EPS of -$1.83 misses by $0.11, revenue of $0.46M misses by $0.01M